ABT-263 has been described to improve efficacy of other anti-tumoral molecules used against pancreatic cancer cells such as in combination with MEK and/or PI3K inhibitors [34], Aurora kinase 1 inhibitor [35], Chk1 inhibitor [36] or TRAIL molecules [37]. Here, CHEK1 is linked to pancreatic neoplasm.